Journal
ONCOTARGET
Volume 5, Issue 17, Pages 7381-7391Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.2290
Keywords
Multiple myeloma; molecular imaging; FDG-PET/CT
Categories
Funding
- DFG [105022/5-1 FUGG]
- Wilhelm Sander-Stiftung [2013.906.1]
- German Research Foundation (DFG)
- University of Wuerzburg
Ask authors/readers for more resources
The aim of this study was to investigate the prognostic value of F-18-fluorodeoxyglucose positron emission tomography-computed tomography (F-18-FDG-PET/CT) in 37 patients with a history of multiple myeloma (MM) and suspected or confirmed recurrence after stem cell transplantation (SCT). All patients had been heavily pre-treated. Time to progression (TTP) and overall survival (OS) were correlated to a number of different PET-derived as well as clinical parameters. Impact on patient management was assessed. Absence of FDG-avid MM foci was a positive prognostic factor for both TTP and OS (p<0.01). Presence of >10 focal lesions correlated with both TTP (p<0.01) and OS (p<0.05). Interestingly, presence of >10 lesions in the appendicular skeleton proved to have the strongest association with disease progression. Intensity of glucose uptake and presence of extramedullary disease were associated with shorter TTP (p=0.037 and p=0.049, respectively). Manifestations in soft tissue structures turned out to be a strong negative predictor for both, TTP and OS (p<0.01, respectively). PET resulted in a change of management in 30% of patients. Our data underline the prognostic value of F-18-FDG-PET/CT in MM patients also in the setting of post-SCT relapse. PET/CT has a significant impact on patient management.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available